Economic Evaluation of FebriDx
Filed with ASX · · 3 pages · English
• Over half the prescriptions issued during 150 million outpatient visits for acute respiratory infections (ARIs) each year in the U.S. are considered medically unnecessary • Antibiotic-related adverse events are responsible for 16% of all outpatient adverse drug consultations • Outpatient visits accounted for the majority of the US$8.8 billion antibiotic-related expenditure in the U.S. in 2015 •
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- U.S FDA Deprioritises EUA Application for CoviDx
- FY21 Full Year Results
- FY21 Full Year Results Investor Presentation
- FY21 Full Year Results Media Release
- FY21 Appendix 4E
Later from Lumos Diagnostics
- Update on Economic Evaluation of FebriDx
- Monthly Activities/Appendix 4C Cash Flow Report
- LDX received authorization to sell CoviDx in Canada
- Lumos Receives Initial Orders for CoviDx In Canada
- Lumos Provides ViraDx and FebriDx Regulatory Update
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics